Lyca CR Tablet (Controlled Release) CR Tablet 82.5 mg is a Product of the Generic Pregabalin

What Is Lyca CR Tablet (Controlled Release) CR Tablet 82.5 mg Indications and Uses?

Film-coated tablet is indicated for: Neuropathic pain associated with diabetic peripheral neuropathy Postherpetic neuralgia Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older Fibromyalgia Neuropathic pain associated with spinal cord injury Controlled release tablet is indicated for: Neuropathic pain associated with diabetic peripheral neuropathy Postherpetic neuralgia

Pharmacology (Source, Chemical and Physical Composition) Of Lyca CR Tablet (Controlled Release) CR Tablet 82.5 mg

Lyca CR Tablet (Controlled Release) CR Tablet 82.5 mg (Pregabalin) is a structural derivative of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). It does not bind directly to GABA A , GABA B or benzodiazepine receptors. Pregabalin binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. Although the mechanism of action of Pregabalin has not been fully elucidated, results in animal studies suggest that binding to the alpha2-delta subunit may be involved in Pregabalin's anti-nociceptive and antiseizure effects.

Drug Interactions of Lyca CR Tablet (Controlled Release) CR Tablet 82.5 mg

Drug interaction with medication : Lyca CR is unlikely to be involved in significant pharmacokinetic drug interactions. Drug interaction with food and others : Not applicable.

Side Effects of Lyca CR Tablet (Controlled Release) CR Tablet 82.5 mg

Most common side effects in adults are dizziness, somnolence, dry mouth, edema, blurred vision, weight gain and thinking abnormal (primarily difficulty with concentration/attention). Most common side effects in pediatric patients for the treatment of partial onset seizures are increased weight and increased appetite.

Precautions And Warnings for Lyca CR Tablet (Controlled Release) CR Tablet 82.5 mg

Angioedema (e.g., swelling of the throat, head and neck) can occur and may be associated with life threatening respiratory compromise requiring emergency treatment. Lyca CR should be discontinued immediately in these cases. Lyca CR should also be discontinued immediately if hypersensitivity reactions (e.g., hives, dyspnea and wheezing) occur. Antiepileptic drugs, including Lyca CR, increase the risk of suicidal thoughts or behavior. Respiratory depression may occur with Lyca CR when used with concomitant CNS depressants or in the setting of underlying respiratory impairment. Patients need to be monitored and dosage adjusted as appropriate. Lyca CR may cause dizziness and somnolence and impair patients ability to drive or operate machinery. Increased seizure frequency or other adverse reactions may occur if Lyca CR is rapidly discontinued. Lyca CR should be withdrawn gradually over a minimum of 1 week. Lyca CR may cause peripheral edema. Caution should be exercised when coadministering Lyca CR and thiazolidinedione antidiabetic agents.

Use During Pregnancy and Lactation

There are no adequate and well-controlled studies with Lyca CR Tablet (Controlled Release) CR Tablet 82.5 mg (Pregabalin) in pregnant women. Pregnant women should be advised of the potential risk to a fetus. Small amounts of pregabalin have been detected in the milk of lactating women. Because of the potential risk of tumorigenicity, breastfeeding is not recommended during treatment with pregabalin.

Therapeutic Class

Adjunct anti-epileptic drugs, Primary anti-epileptic drugs

Storage Conditions of It

Keep in a cool & dry place (below 30°C), protected from light & moisture. Keep out of the reach of children.